unknown
Stage
About
ArkVax develops advanced glycan-based glycoconjugate vaccines for animals using bacterial glycoengineering to improve vaccine potency and breadth while addressing antimicrobial resistance and zoonotic disease protection.
Explore ArkVax's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.